Radiology and Imaging Sciences

Staff Pages

Chang Paik, PhD
Senior Scientist, Nuclear Medicine Radiopharmaceutical Lab
Radiology and Imaging Sciences

Academic Degrees
BS, Inha Institutes of Technology, Inchon, Korea
PhD, University of California,
Santa Cruz

Email: cpaik@cc.nih.gov

Phone: 301-496-1426

Biosketch

Dr. Chang Hum Paik earned his BS in Chemical Engineering from Inha Institutes of Technology, Inchon, Korea and his PhD in Physical Organic Chemistry from University of California, Santa Cruz.

After further training in interdisciplinary fields involving biochemistry, immunology, pharmacology, physiology, and radiochemistry, he pursued his research and teaching career in Radiopharmaceutical Sciences as a faculty member in Nuclear Medicine at the George Washington University Medical Center. There, he developed various methods to synthesize and to use radiolabeled antibodies for tumor detection and therapy. Dr. Paik moved in 1989 to the Nuclear Medicine Department at the NIH Clinical Center to head the Research Radiopharmacy and Antibody Radiopharmaceutical Section.

The major focus of Dr. Paik’s research has been on the synthesis of tumor specific radiopharmaceuticals and the investigation of important chemical and pharmacological parameters of radiopharmaceuticals to improve tumor uptake and to reduce uptake in organs, thereby enhancing tumor detection sensitivity and minimizing radiation exposure to normal organs. In addition, Dr. Paik and his team have been performing translational research on using specific monoclonal antibodies as radiopharmaceuticals to detect and treat various tumors in Phase 0 and Phase I/II clinical studies at the NIH Clinical Center in collaboration with NCI scientists.

Selected Honor and Awards

Editorial Board, Nuclear Medicine and Biology, 1992-present

Editorial Board, Nuclear Medicine and Molecular Imaging, 2010-present

Chair, CC Animal Care and Use Committee, 1994-1996; member, CCACUC, 1990-present

Selected Publications

Book and Book Chapters

Paik CH, Eckelman WC, Reba RC: Important Chemical Variables for Labeling Antibody with In-111 and Tc-99m, In Radiolabeled Monoclonal Antibodies for Imaging and Therapy. Srivastava S, Editor, Plenum Publishing Co., New York, New York, 1988.

Quadri SM, Paik CH, Reba RC and Hong WP: Optimization of Biodistribution by Introducing Different Chemical Linkages between Antibody and In-111 Chelate, In Cancer Imaging with Radiolabeled Antibodies. Goldenberg DM, Editor, Kluwer Academic Publishers, Norwell, MA, 1990, p 201-213.

Eckelman WC, Steigman J and Paik CH: Radiopharmaceutical Chemistry, In Nuclear Medicine, Diagnosis and Therapy, Harbert JC, Eckelman WC and Neumann RD, Editor, Thieme Medical Publishers, Inc., New York 1996, p 213-265.

Eckelman WC, Steigman J and Paik CH: Radiopharmaceuticals, In Diagnostic Nuclear Medicine, Third Ed, Vol 1, Sandler MP, Cleman RE, Wackers FJTH, Patton JA, Gottschalk A, Hoffer PB, Editors, Williams and Wilkins, Baltimore, 1996 p 199-216.

Journal Articles

Paik CH, Ebbert MA, Lassman CR, Murphy PR, Reba RC, Eckelman WC, Pak KY, Powe J, Steplewsi A, Koprowski H: Factors influencing DTPA conjugation to antibodies via cyclic DTPA anhydride. J Nucl Med 24: 1158-1163 (1983).

Paik CH, Hong JJ, Heald SC, Reba RC, Steigman J, Eckelman WC: The labeling of high affinity sites of antibodies with Tc-99m. Int J Nucl Med Biol. 12: 3-8, 1985.

Paik CH, Yokoyama K, Reynolds JC, Quadri SM, Min CY, Shin SY, Maloney PJ, Larson SM and Reba RC: Reduction of Background Activities by Introduction of a Diester Linkage between Antibody and a Chelate in Radioimmunodetection of Tumor. J Nucl Med 30: 1693-1701, 1989.

Juweid M, Nuemann RD, Paik CH, Perez-Bacete MJ, Sato J, van Osdol W and Weinstein JN: Micropharmacology of Monoclonal Antibodies in Solid Tumors: Direct Experimental Evidence for a Binding Site Barrier. Cancer Res 52:5144-5153, 1992.

Kinuya S, Jeong JM, Garmestani K, Saga T, Camera L, Brechbiel MW, Gansow OA, Carrasquillo JA, Neumann RD and Paik CH: Effect of Metabolism on Retention of In-111 Labeled MoAb in Liver and Blood. J Nucl Med 35:1851-1857, 1994.

Yoo TM, Chang HK, Choi CW, Webber KO, Le N, Kim IS, Eckelman WC, Pastan I, Carrasquillo JA and Paik, CH: Tc-99m Labeling and Biodistribution of Anti-Tac Disulfide-Stabilized Fv Fragment. J Nucl Med 1997; 38:294-300.

Kim MK, Song BJ, Seidel J, Soh Y, Jeong K-S, Kim I-S, Kobayashi H, Green MV, Carrasquillo JA, Paik CH. Use of Tc-99m-mercaptoacetyltriglycine (MAG3)-biocytin hepatobiliary scintigraphy to study the protective effect of a synthetic enzyme inhibitor on acute hepatotoxicity in mice NUCL MED BIOL 1998;25: (6) 561-568.

Kim IS, Yoo TM, Kobayashi H, Kim M-K, Le N, Wang Q-C, Pastan I, Carrasquillo JA, Paik CH. Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with Tc-99m. BIOCONJUGATE CHEM 1999;10: (3) 447-453.

Kobayashi H, Kim IS, Drumm D, Kim M-K, Paik DS, Le N, Waldmann TA, Carrasquillo JA, Paik CH. Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment. J NUCL MED 1999;40: (5) 837-845.

Carrasquillo JA, White JD, Paik CH, et al. Similarities and differences in In-111- and Y-90-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J NUCL MED 1999;40: (2) 268-276.

Pai-Scherf LH, Carrasquillo JA, Paik CH, Gansaw O, Whatley M, Pearson D, Webber K, Hamilton M, Allegra C, Brechbiel M, Willingham MC, Pastan I. Imaging and phase I study of In-111 and Y-90 labeled anti-LewisY monoclonal antibody B3. Clin Cancer Res 2000;1720:1720-1730.

Kim M-k, Jeong H-j, Kao C-h K, Yao Z, Paik DS, Pie JE and Kobayashi H, Waldman TA, Carrasquillo JA and Paik CH. Improved renal clearance and tumor targeting of Tc-99m-labeled monoclonal antibody Fab by chemical modifications. Nucl Med Biol 2002;29:139-146.

Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, Lin Y, Park L, Brechbiel MW, Pastan I, Paik CH, Carrasquillo JA. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med. 2005;46(7):1201-1209.

Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo CA, Jang BS, Le N, Ho M, Xiang L, Pastan I. Synergistic Anti-tumor Activity of Taxol and Immunotoxin SS1P in Tumor Bearing Mice. Clin Cancer Res. 2006; 12 (15):4695-4701.

Barrett T, Koyama Y, Hama Y, Shin IS, Jang BS, Paik CH, Urano Y, Choyke PL, Kobayashi H. In vivo diagnosis of EGF receptor expression with a “cocktail” of optically labeled monoclonal antibodies. Clin Cancer Res. 2007;13(22):6639-6648.

Jang BS, Lim E, Park SH, Shin IS, Danthi SN, Hwang IS, Le N, Yu S, Xie J, Li KCP, Carrasquillo JA., Paik CH. Radiolabeled high affinity peptidomimetic antagonist selectively targets αvβ3 receptor-positive tumor in mice. Nucl Med Biol. 2007; 34(4):363-370.

Shin IS, Jang BS, Danthi SN, Xie J, Yu S, Le N, Maeng JS, Hwang IS, Li KCP, Carrasquillo JA, Paik CH. Use of antibody as carrier of oligomers of peptidomimetic αvβ3 antagonist to target tumor-induced neovasculature. Bioconjugate Chem. 2007; 18(3):821-828.

Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J and Hodge JW. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunology Immunotherapy. 2008;57:1173–1183

Khaibullina A, Jang BS, Sun H, Le N, Yu S, Frenkel V, Carrasquillo JA, Pastan I, Li KCL, Paik CH. Pulsed high intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice. J Nucl Med. 2008 Feb;49(2):295-302.

Di Mascio M, Paik CH, Carrasquillo JA, Maeng JS, Jang BS, Shin IS, Srinivasula S, Byrum R, Neria A, Kopp W, Catalfamo M, Nishimura Y, Reimann K, Martin M, Lane HC. Non-invasive in vivo imaging of CD4 cells in SHIV infected non-human primates. Blood. 2009 Jul 9;114(2):328-37.

Zhang M, Yao Z, Garmestani K, Yu S, Goldman CK, Paik CH, Brechbiel MW, Carrasquillo JA, Waldmann TA. Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma. Cancer Biother Radiopharm. 2009 Jun;24(3):303-9.

Kosaka N, Ogawa M, Paik DS, Paik CH, Choyke PL, Kobayashi H. Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer. Cancer Sci. 2010 Mar;101(3):820-5.

Shin IS, Maeng JS, Jang B-S, Cheng K, You E, Li KCP, Wood B, Carrasquillo JA, Danthi SN, Paik CH. 99mTc-labeling of Peptidomimetic Antagonist to Selectively Target αvβ3 Receptor-Positive Tumor: Comparison of PDA and EDDA as co-Ligands. Curr Radiopharm. 2010 Jan 1;3(1):1-8.

Shin IS, Lee SM, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, Hassan R, Campo MF, Albone EF, Choyke PL, Pastan I, Paik CH. Effect of chelator conjugation level and injection dose on tumor and organ uptake of (111)In-labeled MORAb-009, an anti-mesothelin antibody. Nucl Med Biol. 2011 Jul 6. [Epub ahead of print].

Hodge JN, Srinivasula S, Hu Z, Read SW, Porter BO, Mican JA, Paik C, Di Mascio M and Sereti I. Decreases in IL-7 levels during ART suggest a primary mechanism of receptor-mediated clearance with IL-7 levels normalizing despite persistent CD4 lymphopenia. Blood. 2011 Sep 22;118(12):3244-53. Epub 2011 Jul 21.

Jang BS, Lee SM, Kim HS, Shin HS, Razjouyan F, Wang S, Yao Z, Pastan I, Dreher MR, Paik CH. Combined modality radioimmunotherapy: synergistic effect of Paclitaxel and additive effect of Bevacizumab. Nucl Med Biol. 2011,  in press.

Chang Paik, PhD

NOTE: PDF documents require the free Adobe Reader.

This page last updated on 06/22/2017

You are now leaving the NIH Clinical Center website.

This external link is provided for your convenience to offer additional information. The NIH Clinical Center is not responsible for the availability, content or accuracy of this external site.

The NIH Clinical Center does not endorse, authorize or guarantee the sponsors, information, products or services described or offered at this external site. You will be subject to the destination site’s privacy policy if you follow this link.

More information about the NIH Clinical Center Privacy and Disclaimer policy is available at http://www.cc.nih.gov/disclaimers.html